CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03742258
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:40.771789+00:00
Published At: 2025-01-29T00:00:00+00:00
Record Updated At: 2025-06-18
Results Posted At: 2025-01-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Diffuse Large B-Cell Lymphoma", "Diffuse Large B-Cell Lymphoma Activated B-Cell Type", "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type", "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-06-18"
protocolSection.identificationModule.nctId: "NCT03742258"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of R-CHOP Plus SYK Inhibitor TAK-659 for the Front-Line Treatment of High-Risk Diffuse Large B Cell Lymphoma (DLBCL)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-01-29"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.